Compare stocks

AUPH vs SVRA

Aurinia Pharmaceuticals Inc and Savara Inc.

Compare the businesses

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Open AUPH dashboard ↗

Savara Inc.

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

Open SVRA dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

New to NexusTrade? Create a free account.

Choose another comparison ↗